NICE has developed a medtech innovation briefing (MIB) on the BD MAX Enteric Bacterial Panel for identifying pathogens in contagious gastroenteritis.
The BD MAX Enteric Bacterial Panel (EBP) is an assay that detects common enteric bacterial pathogens (which can cause gastroenteritis) from stool samples in 2–3 hours; current standard culture methods take several days. Three fully-published diagnostic test accuracy studies suggested that the BD MAX EBP has higher sensitivity than culture-based methods for detecting bacterial pathogens in gastroenteritis. The cost of running each sample using the BD MAX EBP is £22.50, excluding VAT. The list price for the BD MAX System platform, on which several molecular diagnostic tests can also be run, is £85,000 excluding VAT.
Medtech innovation briefings provide a description of the medical technology, including its likely place in therapy, the costs of using the technology and a critical review of the strengths and weaknesses of the relevant published evidence.
Their purpose is to provide objective information on device and diagnostic technologies to aid local decision-making by clinicians, managers and procurement professionals. By making this information available, NICE helps to avoid the need for NHS organisations to produce similar information for local use.
Medtech innovation briefings are not NICE guidance. They differ in format, contain no judgement on the value of the technology and do not constitute a guidance recommendation.
MIBs are commissioned by NHS England and produced in support of the NHS 5 Year Forward View, specifically as one of a number of steps which will accelerate innovation in new treatments and diagnostics.